We at Alfred are proud to have supported Ikerian AG in their successful Series A Extension financing round. The negotiations were expertly led by Thierry Barbey and Sandro Stich.

Ikerian's Series A Extension final close at USD 6.18M (CHF 5.65M) introduces a new lead investor, the Corporate Venture Capital arm of Topcon Healthcare, Inc.

These funds will support the continued development and commercial rollout of RetinAI Discovery® in ophthalmology and optometry, as well as Ikerian's expansion into new therapeutic areas, prioritizing neurodegenerative disorders, vascular conditions, and rare diseases.

"The successful closing of this financing confirms the importance of our AI technology to re-invent workflows for clinical and pharmaceutical research to support more efficient and effective patient care." – Dr. Carlos Ciller, Chairman and CEO of Ikerian AG.

We offer our heartfelt congratulations to the entire Ikerian team and express our gratitude for the privilege of supporting such a visionary and forward-looking company. We eagerly anticipate witnessing the remarkable strides you will make with this newfound capital.

Team

Thierry Barbey, Founding Partner, Zürich

Sandro Stich, Senior Associate, Zürich

About Ikerian

RetinAI Medical AG has been rebranded as Ikerian AG, aiming to spearhead development beyond ophthalmology, with its wholly-owned subsidiary, RetinAI U.S. Inc., focusing on the ophthalmology and optometry market.

Contact

info@alfred.ch

+41 44 499 0050

Bahnhofplatz 1, 8001 Zürich

About Alfred

Alfred is an innovative new player in the venture advisory space. We combine legal advice with strategic guidance to empower founders, entrepreneurs and investors in an integrated and holistic way that breaks away from traditional advisory services.

Our clients are early stage technology ventures, founders, entrepreneurs or investors from Switzerland and abroad who look for a trusted partner to support them with effective and actionable advice.

Contact us today for a free discovery call.